NCT04598321 - BrUOG 390: Neoadjuvant Treatment With Talazoparib | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 29, 2021

Primary Completion Date

November 30, 2022

Study Completion Date

December 6, 2022

Conditions

BRCA1 MutationBRCA2 MutationOvarian CancerFallopian Tube CancerHigh Grade Serous Carcinoma

Interventions

DRUG

Talazoparib Oral Capsule

An orally available PARP inhibitor for the treatment of advanced breast cancer with germline BRCA mutations.

Trial Locations (2)

Rhode Island Hospital, Providence

Women & Infants Hospital, Providence